Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Baxter
McKinsey

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LYSERGIC ACID DIETHYLAMIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Lysergic Acid Diethylamide

Trial ID Title Status Sponsor Phase Summary
NCT00920387 Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety Completed Multidisciplinary Association for Psychedelic Studies Phase 2 This study will find out whether psychotherapy combined with lysergic acid diethylamide (LSD) is safe and is helpful in people who are anxious because they have a potentially fatal disease. The study will measure anxiety and quality of life before and after people have two sessions with either full or active placebo dose of LSD. They expect LSD-assisted psychotherapy to reduce anxiety and improve quality of life.
NCT01878942 Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study Completed University Hospital, Basel, Switzerland Phase 0 The purpose of this study is to characterize the acute psychological, physiological, endocrine, and pharmacokinetic, as well as long-term psychological effects of LSD in humans.
NCT02308969 Neuronal Correlates of Altered States of Consciousness Completed University Hospital, Basel, Switzerland Phase 0 The aim of the present study is to assess the neuronal correlates of alterations in waking consciousness pharmacologically induced by a 5-hydroxytryptamine (HT)2A receptor agonist in healthy subjects using functional magnetic resonance imaging (fMRI).
NCT02451072 The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers Completed Psychiatric University Hospital, Zurich N/A Aim of the present study is to investigate the neuronal correlates of self and of personal meaning as well as the role of the serotonin (5-HT) 2A receptor system in these processes using functional magnetic resonance imaging (fMRI) and psychometric and cognitive measures.
NCT03019822 Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing Active, not recruiting University Hospital, Basel, Switzerland Early Phase 1 The study will test the effect of dopamine, serotonin, and direct 5-HT2A receptor stimulation on empathy, mood perception, and amygdala activity to fearful stimuli. In addition, we predict associations between subjective effects/alterations in emotion processing tests and functional imaging (fMRI) activity.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Lysergic Acid Diethylamide

Condition Name

Condition Name for
Intervention Trials
Healthy 7
Cluster Headache 1
Anxiety Disorders 1
Anxiety 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Anxiety Disorders 2
Disease 1
Depressive Disorder, Major 1
Depressive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lysergic Acid Diethylamide

Trials by Country

Trials by Country for
Location Trials
Switzerland 7
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lysergic Acid Diethylamide

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 4
Phase 1 1
Phase 0 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 4
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lysergic Acid Diethylamide

Sponsor Name

Sponsor Name for
Sponsor Trials
University Hospital, Basel, Switzerland 6
Matthias Liechti 2
Multidisciplinary Association for Psychedelic Studies 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Other 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Merck
AstraZeneca
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.